Related by context. All words. (Click for frequent words.) 68 statistically significant 68 noninferiority 65 reach statistical significance 64 primary endpoint 63 clinically meaningful 62 achieve statistical significance 62 non inferiority 61 efficacy endpoint 61 secondary endpoint 61 primary efficacy endpoint 59 achieved statistical significance 59 statistical significance p = 58 clinical endpoints 58 prospectively defined 58 statistical significance p 58 secondary efficacy endpoints 58 prespecified 58 efficacy endpoints 57 primary endpoints 57 primary efficacy endpoints 57 virologic response 57 statistically significant differences 57 secondary endpoints 56 antipsychotic efficacy 56 virologic failure 56 periprocedural MI 56 subgroup analyzes 56 nonsignificant 56 statistically significant reduction 55 rolofylline 55 Hb A1C 55 univariate 55 viral kinetics 55 attain statistical significance 55 virological response 55 univariate analysis 55 HbA 1c 54 statistically significant p = 54 Kaplan Meier analysis 54 null hypothesis 54 LVEF 54 mg dose 54 interobserver reliability 54 CR nPR 54 Cmax 54 clinically meaningful improvement 54 surrogate endpoint 54 surrogate markers 54 hemoglobin A1c levels 53 HbA1c 53 limiting toxicity 53 dose proportionality 53 serum concentrations 53 HbA1c levels 53 composite endpoint 53 complete cytogenetic response 53 clinically relevant 53 statistically significant improvement 53 multivariate Cox 53 HOMA IR 53 nonrandomized 53 efficacy 53 NIHSS 53 antibody titer 52 plasma pharmacokinetics 52 sustained virologic response 52 clinically meaningful differences 52 ticagrelor 52 virologic 52 randomized clinical trials 52 serum uric acid 52 tipranavir 52 multivariable analysis 52 generalizability 52 platelet inhibition 52 platelet reactivity 52 serum calcium 52 noninferior 52 active comparator 52 nonfatal MI 52 apremilast 52 seroprotection 52 iniparib 52 statistically nonsignificant 52 TIMI 52 sustained virological response 52 eplerenone 52 Subgroup analyzes 52 6MWD 51 serum vitamin D 51 sUA 51 A1c levels 51 SIMPADICO 51 meta analyzes 51 NYHA functional class 51 selenium supplementation 51 secondary efficacy endpoint 51 pharmacodynamic 51 residual confounding 51 nonresponders 51 nmol L 51 Non inferiority 51 nmol liter 51 FDA defined valvulopathy 51 mL/min/#.# m 2 51 doxorubicin docetaxel 51 lumbar spine BMD 51 Randomized clinical trials 51 placebo 51 definite stent thrombosis 51 intraobserver 51 PSA kinetics 51 pCR 51 median PFS 51 creatinine levels 51 PSA nadir 51 dose limiting toxicities 51 P = .# 51 MMSE score 51 univariate analyzes 51 morphometric vertebral fractures 51 statistically significant p 51 troponin T 51 adenoma recurrence 51 ACR# [002] 51 nonsignificant trend 51 DLTs 51 neutrophil counts 51 Primary endpoints 51 chi squared 51 HBeAg seroconversion 51 progression TTP 51 HbA1C levels 51 cardioprotective effects 51 undetectable viral load 51 convergent validity 51 mITT population 51 glycated hemoglobin 51 plasma concentrations 51 HIV RNA 51 EDSS score 51 bivariate 51 dyssynchrony 51 genotypic resistance 51 statistically significant superiority 51 ACR# response 51 Subgroup analysis 50 serum urate 50 tapentadol ER 50 conditional logistic regression 50 HbA 1C 50 ANOVA 50 alanine aminotransferase ALT 50 NIHSS score 50 creatinine ratio 50 d dimer 50 Doxil ® 50 tocilizumab 50 serum creatinine levels 50 HER2 expression 50 pharmacodynamic endpoints 50 timepoint 50 SVR# 50 paricalcitol 50 #ng/ml 50 serum urate levels 50 homocysteine concentrations 50 imatinib therapy 50 nondiabetic patients 50 analgesic efficacy 50 baseline HbA1c 50 Bonferroni correction 50 locoregional recurrence 50 oxycodone CR 50 AST ALT 50 periprocedural 50 hydroxyvitamin D levels 50 ACR# responses 50 PREZISTA r arm 50 exhaled nitric oxide 50 enoximone 50 lipid lowering drugs 50 procalcitonin 50 post hoc 50 urinary N telopeptide 50 logistic regression models 50 interobserver agreement 50 ADAS cog 50 desvenlafaxine succinate 50 viral load 50 HbA1C 50 peg interferon 50 dexpramipexole 50 PASI scores 50 fondaparinux 50 CDAI score 50 Pharmacokinetic 50 placebo p = 50 PSADT 50 CCyR 50 TOP2A 50 rapid virologic response 50 methotrexate monotherapy 50 subanalysis 50 IOP lowering 50 dose clopidogrel 50 μmol L 50 clazosentan 50 g dL 50 viral kinetic 50 IV bisphosphonates 50 p = #.# [002] 50 AEGR 50 Xinlay 50 prespecified criteria 50 FOLPI 49 infarct size 49 placebo controlled trials 49 tecarfarin 49 RCTs 49 antihypertensive therapy 49 non squamous histology 49 clinically meaningful improvements 49 logistic regression analyzes 49 HbA 1c levels 49 cTnI 49 tHcy 49 QTcF 49 mg doses 49 lintuzumab 49 VADT 49 SCr 49 locoregional disease 49 Maximum Tolerated Dose 49 radiographic progression 49 carotid intima media 49 CD4 + cell 49 randomized trials 49 QT QTc 49 pharmacokinetics PK 49 EDSS 49 #mg/day [001] 49 Crohn Disease Activity 49 pharmacodynamic PD 49 correlational 49 serum phosphate levels 49 placebo controlled clinical 49 pharmacokinetic equivalence 49 ADAS Cog 49 STRIDE PD 49 binary restenosis 49 carotid IMT 49 estimated GFR 49 endometrial thickness 49 TNSS 49 CLBP 49 titers 49 plasma leptin 49 CI -#.# 49 CVD mortality 49 creatinine 49 antidepressant efficacy 49 hemoglobin concentrations 49 YMRS 49 posttreatment 49 elagolix 49 mg kg dose 49 PSA velocity 49 lymph node involvement 49 achieved ACR# 49 DAS# [002] 49 serum phosphorus 49 ALLHAT 49 teriflunomide 49 maximally tolerated dose 49 MDRD 49 MMSE 49 Kaplan Meier curve 49 DAS# remission 49 ARB telmisartan 49 mg BID dose 49 pharmacokinetic PK 49 systolic BP 49 BENICAR HCT 49 HORIZONS AMI trial 49 RE LY ® 49 baminercept 49 insulin glargine 49 undetectable HCV RNA 49 hemoglobin A1c HbA1c 49 NNRTI resistance 49 QTc 49 thromboembolic events 49 Kaplan Meier survival 48 multivariate analyzes 48 coronary calcification 48 Kaplan Meier curves 48 bicifadine 48 lowering homocysteine 48 neoadjuvant chemotherapy 48 interrater reliability 48 detectable HCV RNA 48 pg ml 48 serum PSA 48 reinfarction 48 seroconversion 48 coronary stenosis 48 logistic regression analysis 48 atrasentan 48 placebo p 48 pharmacokinetic parameters 48 abciximab 48 eGFR 48 Kruskal Wallis test 48 HBeAg 48 temsirolimus 48 alteplase 48 A1C levels 48 #.#/#.# mmHg [001] 48 thyroglobulin 48 PNH patients 48 response CCyR 48 MADRS score 48 subgroup 48 valsartan 48 neurologic progression 48 symptomatic VTE 48 multivariable Cox 48 specific antigen PSA 48 randomized clinical 48 dose Iluvien 48 LDL particle 48 mcg dose 48 Index CDAI 48 nonrandomized studies 48 CD4 counts 48 ng mL 48 intima media thickness 48 mg/m2 dose 48 PREZISTA r 48 glomerular filtration rate 48 modified REGENESIS Phase IIb 48 CTEPH 48 peginterferon 48 remission CR 48 mRS 48 nanomolar 48 glycated hemoglobin levels 48 creatinine clearance 48 adalimumab 48 randomized blinded 48 microalbuminuria 48 intact parathyroid hormone 48 urate levels 48 ATACAND 48 femoral neck BMD 48 pg mL 48 β blockers 48 QTc prolongation 48 histologic 48 SNP rs# [002] 48 XIENCE V PROMUS Stent 48 ACCORD Lipid 48 WOMAC pain 48 prognostic significance 48 fraction LVEF 48 sunitinib 48 S/GSK# 48 mucosal healing 48 NATRECOR ® 48 velafermin 48 1mg dose 48 glycemia 48 recurrent VTE 48 symptom severity 48 FOLFOX4 48 timepoints 48 advanced adenomas 48 undetectable HBV DNA 48 NAbs 48 NEVO ™ 48 Viral load 48 complete cytogenetic 48 fructosamine 48 nondiabetics 48 neuroregenerative 48 SGRQ 48 #mg QD [001] 48 trials RCTs 48 preoperative PSA 48 multivariate logistic regression 48 nonparametric 48 leukocyte count 48 Lp PLA2 48 glargine 48 virological suppression 48 proteinuria 48 hemoglobin A1C 48 antibody titers 48 androgen suppression 48 Sensitivity analyzes 48 log# copies mL 48 rEEG 48 randomized controlled trials 48 baseline FEV 48 confirmatory clinical 48 PCa 48 aspartate aminotransferase 48 simvastatin ezetimibe 48 lipid profiles 48 tumor progression TTP 48 diastolic blood pressures 48 #mg BID [001] 48 cardiovascular mortality 48 serum cholesterol 48 multicentre randomized 48 certolizumab 48 ng ml 48 tolvaptan 48 pharmacodynamic effects 48 antioxidant supplementation 48 pretest probability 48 IPSS 48 trastuzumab Herceptin ® 48 cabazitaxel 48 PREVENT IV 48 sensitivity specificity 48 cystatin C 48 endoscopic remission 48 serum phosphorous 48 postoperative chemotherapy 48 aminotransferase ALT 48 Multivariate analysis 48 Timed Walk 48 canakinumab 48 mg dL 48 elevated CRP 48 maximal dose 47 biochemical recurrence 47 systolic dysfunction 47 corrected QT interval 47 antitumor effect 47 interobserver 47 hepatic fibrosis 47 atheroma volume 47 OGTT 47 cerebrovascular events 47 CYP#C# genotype 47 tumor histology 47 HDRS 47 tirofiban 47 tipranavir r 47 mg BID 47 cardiovascular morbidity 47 antihypertensive agents 47 Secondary efficacy endpoints 47 Randomized trials 47 CIMZIA TM 47 lopinavir r 47 randomized controlled 47 SUVmax 47 EQ 5D 47 everolimus eluting stents 47 QTc intervals 47 levosimendan 47 tumor shrinkage 47 serum testosterone 47 clinically meaningful efficacy 47 intima media thickness IMT 47 Pharmacokinetic parameters 47 Ishak fibrosis score 47 tumor recurrence 47 eptifibatide 47 virologic suppression 47 hsCRP levels 47 ALSFRS R 47 CHAMPION PLATFORM 47 sirolimus eluting stent 47 fosamprenavir 47 Rating Scale BPRS 47 serum creatinine 47 SYNTAX trial 47 p = 47 sirolimus eluting stents 47 QIDS SR 47 DAPT 47 pioglitazone 47 serum phosphate 47 clinically insignificant 47 baseline LDH 47 #.#mg/dL 47 NLX P# 47 liver histology 47 nomograms 47 FDG PET imaging 47 subclinical atherosclerosis 47 #.#ng/ml 47 plasma glucose levels 47 urate lowering therapy 47 CR CRu 47 rALLy trial 47 Baseline characteristics 47 pulmonary exacerbations 47 mapatumumab 47 rt PA 47 Oncotype DX Recurrence Score 47 genotypic 47 confidence intervals CIs 47 virological failure 47 airway responsiveness 47 ACUITY trial 47 nilotinib 47 BPH Symptom Score 47 serum clusterin levels 47 elevated ALT 47 nicardipine 47 MDRD equation 47 albumin excretion 47 histopathological 47 postprocedure 47 copies mL 47 elevated troponin 47 mRCC 47 plasma cortisol 47 covariate 47 #mg BID [003] 47 chemoradiotherapy 47 revascularizations 47 lymphocyte counts 47 CIMZIA ™ 47 aminotransferases 47 GOUT 47 regression analyzes 47 fluvastatin 47 locoregional 47 PCWP 47 unfractionated heparin 47 dosage regimens 47 HI titers 47 CRESTOR #mg 47 neoadjuvant 47 log# reduction 47 adiponectin levels 47 paclitaxel eluting stents 47 SHBG levels 47 febuxostat 47 glycosylated hemoglobin HbA1c 47 comparator arm 47 peginterferon alfa 2a 47 Solid Tumors criteria 47 peginterferon alfa 2b 47 PRIMO CABG2 47 evaluable subjects 47 HBeAg negative patients 47 cediranib 47 azacitidine 47 nab paclitaxel 47 neostigmine 47 ipsilateral stroke 47 FDG PET scans 47 visceral metastases 47 LEXIVA r 47 apolipoprotein B 47 DMARD 47 DSMB 47 Ereska 47 Xalatan R 47 serum potassium 47 ABC/3TC 47 prespecified secondary 47 glycated hemoglobin HbA1c 47 vertebral fracture 47 #OHD 47 prospective randomized controlled 47 beta carotene supplementation 47 lactate dehydrogenase LDH 47 MAGE A3 ASCI 47 CIMZIA TM certolizumab pegol 47 #Gy 47 androgen deprivation 47 recurrent ischemia 47 insulin detemir 47 AUC0 47 iloprost 47 postintervention 47 raltegravir 47 alanine aminotransferase 47 placebo controlled clinical trials 47 dose statin therapy 47 #mg dose [001] 47 cilostazol 47 HAQ DI 47 AUA Symptom Score 47 Sustained virologic response 47 Pharmacokinetic studies 47 serum HBV DNA 47 evaluable 47 corneal staining 47 pharmacodynamics PD 47 double blinded placebo 47 p = .# [002] 47 virologic responses 47 FEV1 47 retinal thickness 47 #mg dose [002] 47 p = #.# [003] 47 EDEMA3 47 AVADO 47 ibandronate 47 unpaired t 47 CD# expression [002] 47 % Confidence Interval 47 favorable pharmacokinetic profile 47 disease progression 47 scintigraphic 47 Montgomery Asberg Depression 47 avosentan 47 left ventricular ejection 47 multivariable adjusted 47 glycosylated hemoglobin 47 Pred Forte 47 proportional hazards 47 CC genotype 47 viral suppression 47 adjuvant therapies 47 Neuropsychiatric Inventory NPI 47 LDL C 47 tertiles 47 statistically significant correlations 46 Randomized controlled 46 serum triglycerides 46 Montgomery Åsberg Depression 46 platelet aggregation 46 TRITON TIMI 46 TAXUS IV 46 SSRI citalopram 46 CK MB 46 antiviral efficacy 46 bivariate analysis 46 hs CRP 46 serum biomarkers 46 GAMMAGARD 46 resected pancreatic cancer 46 gemcitabine carboplatin 46 ertapenem 46 MADIT CRT trial 46 surrogate marker 46 ZOMIG Nasal Spray 46 low dose cytarabine 46 biological plausibility 46 seropositive patients 46 KRAS mutation 46 ritonavir boosted 46 randomisation 46 colorectal adenoma 46 Multivariate analyzes 46 EBRT 46 serum BDNF 46 g dl 46 randomized multicenter trial 46 albumin excretion rate 46 Thrombolysis 46 anti leukemic 46 sweat chloride 46 cytogenetic response 46 μg L 46 pegylated liposomal doxorubicin 46 μg dose 46 hematologic toxicity 46 DAS# CRP 46 EUS FNA 46 hsCRP 46 bivalirudin 46 TLUS 46 GIK infusion 46 urine NGAL 46 riociguat 46 intravesical therapy 46 p = .# [001] 46 vismodegib 46 KRAS status 46 renal toxicity 46 carotid stenosis 46 Her2/neu 46 Hazard Ratio HR 46 nucleoside naive patients 46 EGFR TKI 46 fulvestrant 46 EGFR mutation status 46 posaconazole 46 IELT 46 vicriviroc 46 F FDG PET 46 HAMD 46 Fasting plasma glucose 46 randomized controlled trials RCTs 46 RE LY trial 46 nmol L. 46 elevated LDH 46 CNS LS 46 NYHA class 46 interindividual variability 46 % CI #.#-#.# [003] 46 arterial thromboembolic events 46 hypercalcemia 46 5-FU/LV 46 hematopoietic cancers 46 annualized relapse 46 liposomal doxorubicin 46 titration regimen 46 non squamous NSCLC 46 noncancer 46 degarelix 46 TMC# C# 46 peak plasma concentrations 46 LPV r 46 Brief Psychiatric 46 oblimersen 46 BMI z 46 transaminases 46 biopsy Gleason 46 Hematologic toxicity 46 adjuvant radiotherapy 46 Univariate analysis 46 subclinical hypothyroidism 46 CoFactor 46 postoperative mortality 46 immunoreactivity 46 pairwise comparisons 46 pegylated interferon alfa 2b 46 Ceplene/IL-2 46 glomerular filtration 46 elotuzumab 46 correlation coefficients 46 chemosensitivity 46 Recurrence Score 46 BRIM3 46 systemic absorption 46 zotarolimus eluting stent 46 p ≤ 46 dietary folate 46 echocardiographic 46 A1c 46 #mg dose [003] 46 IL#B 46 tolerated dose MTD 46 diastolic pressures 46 arterial thickening 46 mCRC patients 46 serum IGF 46 CYP#D# genotype 46 fasting glucose 46 pharmacodynamic parameters 46 Secondary endpoints 46 ADCS ADL 46 oral Xeloda 46 NPH insulin 46 atorvastatin #mg 46 ILLUMINATE 46 anemia hemoglobin 46 randomization 46 stent binary restenosis 46 Phase 2a trial 46 plasma folate 46 GSK# [001] 46 CK # plasma concentrations 46 HBV DNA levels 46 ruboxistaurin 46 nonfasting triglycerides 46 cobicistat 46 K ras mutations 46 ng dL 46 fasting blood glucose 46 darunavir 46 lymphocyte count 46 sirolimus stent 46 transaminase elevations 46 log# 46 preclinically 46 HAM D# 46 prostate cancer PCa 46 pharmacokinetic interaction 46 lipid parameters 46 docetaxel pretreated 46 infliximab 46 tiotropium 46 multivariate adjustment 46 IGFBP 3 46 mcg BID 46 mycophenolate mofetil 46 allele frequencies 46 placebo fluoxetine 46 MERLIN TIMI 46 ataluren 46 symptomatic intracerebral hemorrhage 46 SLNB 46 mcg kg 46 Stent thrombosis 46 imatinib 46 macroalbuminuria 46 #OHD levels 46 mg RDEA# 46 TOLAMBA 46 tertile 46 Unified Parkinson Disease 46 undetectable viral loads 46 FOLFIRI 46 ETDRS 46 death reinfarction 46 intravenous dosing 46 lowest tertile 46 hemoglobin concentration 46 cranial irradiation 46 galiximab 46 CANCIDAS 46 CLA supplementation 46 MACCE 46 myocardial infarctions 46 hormone receptor status 46 osteopenic 46 #/#mmHg 46 plasma lipid 46 urine albumin 46 chlorambucil 46 ramipril 46 Zevalin consolidation 46 cTnT levels 46 gadobutrol 46 stratifying patients 46 radiographic outcomes 46 nodular partial response 46 complete remissions 46 angiographic outcomes 46 AVERROES 46 pharmacodynamic properties 46 pharmacokinetic characteristics 46 hippocampal volume 46 MADRS 46 clinically meaningful reductions 46 arterial elasticity 46 optimal dosing 46 serum cotinine 46 NIH CPSI 46 biologic plausibility 46 serum folate concentrations 46 unmeasured confounding 46 serum retinol 46 cisplatin vinorelbine 46 TACE 46 ziprasidone 46 albumin creatinine ratio 46 microsatellite instability 46 Darusentan 46 TNF antagonist 46 macrovascular 46 sd = 46 pregabalin 46 observational studies 46 D dimer 46 abacavir lamivudine 46 rHuPH# 46 #mmHg [001] 46 protease inhibitor mutations 45 serum parathyroid hormone 45 GFT# 45 Logistic regression 45 nerve conduction velocity 45 Plasma concentrations 45 endoscopic gastric ulcers 45 prior chemotherapy regimens 45 CINQUIL 45 lumiracoxib 45 metabolic parameters 45 anagrelide 45 pure fructose 45 platelet counts 45 blood Phe 45 ivabradine 45 mean baseline HbA1c 45 unmeasured confounders 45 laboratory abnormalities 45 hip BMD 45 EDEMA3 trial 45 thrombolytic therapy 45 Negative Syndrome 45 lamotrigine 45 silent myocardial ischemia 45 viral loads 45 fosbretabulin 45 serum sodium 45 ± SEM 45 amprenavir 45 diastolic pressure 45 TNF inhibitor 45 elevated bilirubin 45 mcg mL 45 epidemiologic studies 45 thiazide diuretics 45 dexmedetomidine 45 Ki# 45 dose escalation 45 HGS ETR1 45 prognostic indicators 45 MoxDuo TM IR 45 nonfasting triglyceride levels 45 reboxetine 45 Logistic regression analysis 45 predefined criteria 45 abatacept 45 SerDes transceivers 45 metastatic RCC 45 nephrotoxicity 45 KRN# 45 TT genotype 45 lipid lowering medications 45 PCPT 45 biochemical relapse 45 serum GGT 45 liver metastasis 45 serum albumin 45 subclinical hyperthyroidism 45 thyrotropin levels 45 Primary Endpoint 45 carotid artery thickness 45 MET amplification 45 TEAEs 45 randomized controlled clinical 45 sipuleucel T 45 epoetin alpha 45 dalteparin 45 therapeutic equivalence 45 serum markers 45 EGFR expression 45 advanced adenoma 45 carotid bruit 45 bendamustine 45 Scale PANSS 45 randomized placebo controlled 45 oral diclofenac 45 standard deviations 45 fasting triglycerides 45 ximelagatran 45 lymph node metastases 45 clobazam 45 inflammatory biomarkers 45 Platelet counts 45 chlorthalidone 45 octreotide LAR 45 χ 45 postop 45 NNT = 45 irbesartan 45 L PPDS 45 cobiprostone 45 RLAI 45 methotrexate therapy 45 Kaplan Meier method 45 dose colchicine 45 systemic embolism 45 antiplatelet agent 45 dasatinib 45 recurrent glioblastoma multiforme 45 cangrelor 45 telmisartan 45 rs# [004] 45 baseline FEV1 45 dose atorvastatin 45 rimonabant #mg 45 neutrophil count 45 ECOG 45 residual platelet reactivity 45 posttest 45 creatine kinase 45 free survival PFS 45 adiponectin concentrations 45 hypoglycemic events 45 lipid lowering therapy 45 comparator 45 APTIVUS r 45 echocardiographic parameters 45 #F FDG PET 45 bosentan 45 splenectomized patients 45 hemoglobin Hb 45 candesartan 45 sirolimus 45 platelet function 45 ancrod 45 P ≤ 45 oral allopurinol 45 LV ejection fraction 45 SPIRIT FIRST 45 antiretroviral naïve 45 prognostic variables 45 safinamide 45 ICD therapy 45 comorbidity 45 mmol L. 45 Bonferroni